LIFE SCIENCE PRODUCTS MARKET ANALYSIS

Life Science Products Market, By Product (Recombinant Proteins (Immune Checkpoint Regulators, Chemokines, Growth Factors, Cytokines, Colony Stimulating Factors, Hormones, Enzymes & Inhibitors, Others), Cell Lines (Immunotherapy Cell Lines, Ion Channel Cell Lines, GPCR Cell Lines, Cell Signaling Pathway Cell Lines, Gene Knockout Cell Lines, Cancer Cell Lines, Others), Antibodies (Immune Checkpoint Antibodies, Epitope Tag Antibodies, Isotype Control Antibodies (Research Use, In-vivo Grade), Primary Antibodies (Research Use, In-vivo Grade), Assay Antibodies (includes secondary antibodies), Others(Viable Tumor Samples, Tumor Tissue Microarrays)), By Application (Drug Discovery & Development, Basic Research, Toxicity Screening, Biopharmaceutical Production, Drug Screening, Tissue Engineering, Forensic Testing), By End User (Biopharmaceutical Companies, Contract Research Organizations (CROs), Academic & Research Institutes, Forensic Science Laboratories, Food & Beverage Companies, Diagnostic Centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Jun 2023
Code : CMI3652
Pages :180
Formats :
Excel and PDF
Industry : Biotechnology

Life Science Products MarketSize and Trends

Global Life Science Products market is estimated to be valued at US 3,178.1 million in 2023 and is expected to exhibit a CAGR of 10.6% during the forecast period (2023-2030). Increase in product launches by key market players is expected to drive the market growth over the forecast period. Moreover, an increase in government and non-government organizations' initiatives to improve access to affordable vision care and an increase in awareness among people regarding eye-related diseases are expected to drive the market growth.

Figure 1. Global Life Science Products Market Share (%), by Product Type, 2023